Childhood factors associated with asthma remission after 30 year follow up

J M Vonk, D S Postma, H M Boezen, M H Grol, J P Schouten, G H Koëter, J Gerritsen

Background: Factors contributing to either “complete” or “clinical” remission of asthma are important to know since there is no cure for the disease.

Methods: A cohort of 119 allergic asthmatic children was examined three times with a mean follow up of 30 years. They were aged 5–14 years at visit 1 (1966–9), 21–33 years at visit 2 (1983–6), and 32–42 years at visit 3 (1995–6). Complete remission of asthma at visit 3 was defined as no asthma symptoms, no use of inhaled corticosteroids, normal lung function (FEV₁ >90% predicted), and no bronchial hyperresponsiveness (PC₁₀ >16 mg/ml). Clinical remission was defined as no asthma symptoms and no use of inhaled corticosteroids.

Results: 22% of the group was in complete remission of asthma at visit 3 and a further 30% was in clinical remission (total 52%). 57% of subjects in clinical remission had bronchial hyperresponsiveness and/or a low lung function. Logistic regression analyses showed that a higher FEV₁ in childhood and more improvement in FEV₁ from age 5–14 to 21–33 were associated with both complete and clinical asthma remission at age 32–42.

Conclusions: Complete remission of asthma was present in a small subset of asthmatics while half the subjects showed clinical remission. Both complete and clinical remission were associated with a higher lung function level in childhood and a higher subsequent increase in FEV₁. These results support the view that defining remission only on the basis of symptoms and medication use will overlook subjects with subclinical active disease and possibly associated airway remodelling.

The paramount aim of asthma management is complete cure. So far, this cannot be achieved with the available treatment. It is therefore important to know which childhood and early adult factors contribute to the best attainable outcome—namely, remission of asthma. Only a few population based studies on the natural history and outcome of asthma are available. Defining remission of asthma generally as absence of respiratory symptoms and asthma medication use. Martin et al found 20% of a group of individuals who frequently wheezed in childhood to be symptom free at age 21, as were 50% of a group that wheezed infrequently in childhood. Twenty one years later, at a mean age of 42 years, these percentages were slightly higher (about 30% and 55%, respectively). Another population-based study on 2300 subjects aged 10–79 years reported that 22% of the group was in complete remission of asthma at visit 3 and a further 30% was in clinical remission (total 52%). 57% of subjects in clinical remission had bronchial hyperresponsiveness and/or a low lung function. Logistic regression analyses showed that a higher FEV₁ in childhood and more improvement in FEV₁ from age 5–14 to 21–33 were associated with both complete and clinical asthma remission at age 32–42.

Methods

Study design and patients

We re-examined a cohort of 119 allergic asthmatic children who were admitted to the outpatient clinic of the paediatric pulmonology department of the University Hospital of Groningen between 1966 and 1969 (visit 1, age 5–14 years). Follow up data were collected between 1983 and 1986 (visit 2, age 21–33 years) and between 1995 and 1996 (visit 3, age 32–42 years). The medical ethics committee of the University Hospital of Groningen approved the study, and all participants gave a written informed consent. Inclusion criteria at visit 1 were having doctor’s diagnosed asthma in a stable condition, parental informed consent for a 5 day stay in hospital, and being able to perform technically satisfactory lung function tests. Exclusion criteria were the presence of specific respiratory diseases (cystic fibrosis or tuberculosis) or other seriously interfering diseases. Before all visits patients had to discontinue their asthma medications for a specified amount of time (short acting β₂ agonists, anticholinergics, cromoglicate: 8 hours; theophylline and oral antihistamines: 24 hours; long acting β₂ agonists: 48 hours). The use of oral and/or inhaled corticosteroids was continued. In the initial
and two follow up visits, measurements were performed using the same protocol.20–22

**Questionnaire**
The Dutch version of the British Medical Research Council’s standard questionnaire was used which is comparable to the European Coal and Steel Community’s questionnaire.13 14 During the third visit the European Community Respiratory Health Study questionnaire was applied as well.15 16 At all visits subjects were interviewed by a trained physician.

**Skin tests, eosinophils, serum IgE**
Intracutaneous skin tests were performed with identical allergen extract batches for house dust, grass pollens, moulds, animal dander, and feather at all visits (Diephuis Laboratory, Groningen, The Netherlands). Since, at the initial visit, the wheal sizes of the skin tests were recorded in 5 mm categories and the original wheals were no longer available, skin tests were considered positive if the largest diameter of the wheal was at least 5 mm. Blood eosinophils were counted in a Bürker counting chamber (Scherf, Cecchinato, Venice, Italy). At visits 2 and 3, serum total IgE was measured by solid phase immunoassay (Pharmacia IgE EIA, Pharmacia Diagnostics A, Sweden). This test was not available at visit 1.

**Lung function**
Measurements of lung function were carried out with a water sealed spirometer (Lode Spirograph type DL; Lode Instruments, Groningen, The Netherlands). The highest value of two valid measurements of FEV1 and slow inspiratory vital capacity (IVC) was recorded. Predicted values used at visit 1 were those of Zapletal16 and at the follow up visits those of the ECCS.21

**Histamine challenge test**
The method of Tipffenau as modified by de Vries and Kno18–20 was used,21–22 as published previously.10–12 The histamine concentration causing a decrease of 10% or more from baseline was taken as threshold value (PC10). The test was terminated when the threshold was reached or when the highest concentration had been given. No test was performed in subjects with an FEV1 <1.5 L. Subjects were considered hyperresponsive if their PC10 was ≤16 mg/ml, a value comparable with PC20 ≤8 mg/ml in the 2 minutes inhalation method of Hargreave.21 22

**Statistical analysis**
“Complete remission” of asthma was defined as having no current wheeze and no asthma attacks in the previous 3 years, no use of inhaled corticosteroids, normal lung function (FEV1 >90% predicted), and absence of BHR (PC10 >16 mg/ml). “Clinical remission” was defined as absence of wheeze and asthma attacks and no use of inhaled corticosteroids.

Logistic regression analyses were performed to investigate the independent effect of different variables on the two types of asthma remission at visit 3. Based on presumed biological importance, the following explanatory variables were selected a priori to be included in these models: FEV1% predicted (per 10%) at visit 1, change in FEV1% predicted (per 10%) from visit 1 to visit 2, male sex, BHR (log PC10) at visit 1, symptoms of wheeze or asthma attacks at visit 2,10 log serum total IgE (IU/l) at visit 2, eosinophilia at visit 1, and smoking habits (pack years) at visit 3. Other logistic regression analyses were performed on the separate components used in defining remission of asthma at visit 3 with the same explanatory variables. All analyses were performed using SPSS (version 11.0.1; SPSS Inc, Chicago, IL, USA).

**RESULTS**
From the original cohort of 119 subjects, three were excluded: one subject suffered from α1-antitrypsin deficiency and all data for two subjects were missing. Of the remaining 116 patients, 94 attended two follow up examinations, six attended only visit 2, and six attended only visit 3. At both visits 2 and 3 the retention rate was 86%. At visit 2, 14 subjects refused to participate and two were lost to follow up. At visit 3, 11 subjects refused, one could not participate because of pregnancy, two were lost to follow up, and two had moved abroad. The characteristics of the subjects studied and those lost to follow up are given in table 1. The percentage of males was lowest in the group with no follow up visits. No other significant differences existed between these groups at baseline. At visit 3, 91 subjects had complete data and were included in the analysis, while nine only responded to the questionnaire. Baseline characteristics were not significantly different between these groups (results not shown).

Figure 1 shows that 20 of the subjects (22%) were in complete remission of asthma at age 32–42 and a further 27 (30%; total of 52%) were in clinical remission. Almost 29% (n = 26) reported symptoms and, of these patients, 54% (n = 14) did not use inhaled corticosteroids. Finally, 20% used inhaled corticosteroids without reporting symptoms.

Logistic regression analyses on remission of asthma and its separate components showed that a higher FEV1% predicted at visit 1 (aged 5–14 years) and a higher increase in FEV1% predicted from visit 1 to 2 (aged 21–33 years) were significantly associated with both complete and clinical remission of asthma at visit 3 (aged 32–42 years; table 2). The odds ratio of 3.02 for FEV1% predicted (per 10%) at visit 1 indicates that the odds of being in complete remission are three times higher for a subject with an FEV1% predicted of 90% at baseline compared with a subject with a baseline FEV1% average of 70%.

<table>
<thead>
<tr>
<th>Table 1 Baseline and follow up characteristics of the study population</th>
</tr>
</thead>
<tbody>
<tr>
<td>Visit 1</td>
</tr>
<tr>
<td>-------------------------------------------------------------</td>
</tr>
<tr>
<td><strong>Visit 1</strong></td>
</tr>
<tr>
<td>Mean (SD) age (years)</td>
</tr>
<tr>
<td>Mean (SD) FEV1% predicted</td>
</tr>
<tr>
<td>Mean (SD) FEV1% predicted</td>
</tr>
<tr>
<td>Sex (% male)</td>
</tr>
<tr>
<td>PC10 &lt;16 mg/ml (% predicted)</td>
</tr>
<tr>
<td>Eosinophilia (% predicted)</td>
</tr>
<tr>
<td>Start symptoms before or at 3 years (%)</td>
</tr>
</tbody>
</table>

*Significantly different from the group with no follow up visits.

†Eosinophils: 0–5 years: ≥500 × 106 cells/l, 6–10 years: ≥400 × 106 cells/l, 11–15 years: ≥350 × 106 cells/l, >15 years: ≥250 × 106 cells/l.
predicted of 80%. Clinical remission was also associated with a higher number of pack years smoked at visit 3. A higher FEV1% predicted at visit 1 and a lower serum total IgE at visit 2 were significantly associated with the absence of BHR at visit 3. Subjects with persistent asthma showed no improvement in lung function from visit 1 to visit 3: mean FEV1 % predicted increased from visit 1 to 73% to 101.5% at visit 3. The difference in lung function from visit 1 to visit 3: mean FEV1% predicted increased from visit 1 to 73% to 101.5% at visit 3. The difference in lung function from visit 1 to visit 3 was about 80% at all visits (table 2). Subjects in complete remission at visit 3 had a near normal FEV1 at all visits: 90% predicted (OR 1.98, 95% CI 1.03 to 3.99) and for the absence of asthma symptoms at visit 3 (OR 1.83, 95% CI 1.04 to 3.24) and of borderline significance for complete remission (OR 1.98, 95% CI 0.96 to 4.09, \( p = 0.07 \)). Removal of lung function parameters from the model did not change these results.

Figure 2 shows the lung function levels for subjects with persistent asthma and those in complete remission at visit 3. Subjects with persistent asthma showed no improvement in lung function from visit 1 to visit 3: mean FEV1% predicted was about 80% at all visits (table 2). Subjects in complete remission at visit 3 had a near normal FEV1 at all visits: 88.6% predicted at visit 1 which increased to 96% at visit 2 and to 101.5% at visit 3. The difference in lung function

<table>
<thead>
<tr>
<th>Table 2</th>
<th>Multiple logistic regression analyses on complete and clinical remission of asthma at visit 3, on no symptoms at visit 3, on no use of corticosteroids at visit 3, and on no BHR at visit 3 (n = 75)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Complete remission* (n = 15 v n = 60)</td>
<td>Clinical remission* (n = 37 v n = 38)</td>
</tr>
<tr>
<td>FEV1 %pred visit 1 (per 10%)</td>
<td>3.02 (1.37 to 6.67)</td>
</tr>
<tr>
<td>FEV1 %pred visit 2 – visit 1 (per 10%)</td>
<td>3.08 (1.43 to 6.61)</td>
</tr>
<tr>
<td>Male sex</td>
<td>0.95 (0.20 to 5.00)</td>
</tr>
<tr>
<td>*log PC_{10} visit 1</td>
<td>1.14 (0.80 to 1.64)</td>
</tr>
<tr>
<td>Symptoms visit 2†</td>
<td>0.50 (0.12 to 2.19)</td>
</tr>
<tr>
<td>Log IgE visit 2</td>
<td>1.16 (0.28 to 4.77)</td>
</tr>
<tr>
<td>Eosinophilia visit 1†</td>
<td>2.09 (0.42 to 10.46)</td>
</tr>
<tr>
<td>Pack years visit 3</td>
<td>1.00 (0.94 to 1.07)</td>
</tr>
</tbody>
</table>

Values are presented as odds ratios with 95% confidence intervals in parentheses.

*Complete remission: no symptoms of wheeze or asthma attacks, no use of inhaled corticosteroids, FEV1% predicted >90%, and absence of BHR.

Clinical remission: no symptoms of wheeze or asthma attacks, no use of inhaled corticosteroids.

†Symptoms of wheeze and/or asthma attacks, no use of inhaled corticosteroids.

‡Eosinophilia: 0–5 years: >500 × 10^6 cells/l, 6–10 years: >400 × 10^6 cells/l, 11–15 years: >350 × 10^6 cells/l, >15 years: >250 × 10^6 cells/l.
between subjects with persistent asthma and subjects with asthma in complete remission was statistically significant at visits 2 and 3.

**DISCUSSION**

We characterised 119 children with allergic asthma three times over a follow up period of 30 years, 91 of whom (76%) with a complete dataset at the third visit. The number of individuals with complete asthma remission at the third visit (that is, no asthma symptoms, no steroid use, normal lung function, and no BHR) appeared to be 22% while a further 30% (in total 52%) was in clinical remission (that is, no asthma symptoms, no steroid use). A higher FEV₁% predicted in childhood (age 5–14) and a larger increase in FEV₁ up to age 21–33 are significantly associated with both complete and clinical remission of asthma at age 32–42 (visit 3).

Studies investigating childhood risk factors for the outcome of asthma usually define remission of asthma in adulthood as a symptom-free state and absence of asthma treatment. With this definition, higher remission rates in adulthood are generally associated with less severe symptoms and better lung function in childhood. Our finding that a better lung function at age 5–14 was significantly associated with both complete and clinical remission of asthma at age 32–42 is in line with this.

We realise that our cohort is a rather selected group of patients with moderate to severe asthma; it is a clinic based sample of allergic asthmatic children who had to agree to a 5 day stay in hospital at recruitment. We must therefore be cautious in generalising these results to the whole population of asthmatic children. Furthermore, the known role of atopy as a risk factor for the persistence of asthma could not be investigated in this atopic cohort.

Subjects with a lower level of lung function in childhood and a smaller subsequent growth of lung function were likely to have persistent asthma at age 32–42. These deficits in lung function level and its development in early life may be the result of various factors including in utero development and early childhood exposures, but may also reflect airway remodelling shortly after the start of the disease. Unfortunately, at the time of the initial visit (1966–69), inhaled corticosteroids were not available. It can be speculated that lung function deficits would have been smaller if these children had received adequate anti-inflammatory treatment shortly after the start of their disease. Nevertheless, there is a small subgroup of patients with complete asthma remission, despite the absence of inhaled steroid treatment. These patients had only a slightly higher lung function in childhood but their subsequent development in lung function is strikingly better than in patients with persistent asthma. It is possible that the structural changes in the airways caused by airway remodelling in this group did not take place at all, or to a lesser extent.

We also performed an analysis on subjects with BHR at baseline, an indirect marker of airway inflammation. The finding that less severe BHR at baseline is associated with a better outcome of the disease in this subgroup supports the idea of less airway remodelling in those with a better prognosis.

Interestingly, asthmatics who had smoked a higher number of pack years were more likely to be in clinical remission and did not use inhaled corticosteroids at visit 3. This can best be explained by the “healthy smoker effect”—that is, those patients with more susceptible airways do not take up smoking or quit early. Alternatively, smokers may have stopped using inhaled corticosteroids, given that smoking is associated with a smaller response to inhaled steroids. This clearly needs further study.

The absence of asthma symptoms in 71% of our subjects was not associated with any of the investigated childhood risk factors. Roorda et al found that 24% of their 406 asthmatic children did not report asthma symptoms after a follow up period of nearly 15 years, and none of the investigated childhood risk factors predicted the asymptomatic state, a finding compatible with the results of our study and that of Panhuysen et al. A comparable prevalence of 28% symptom-free rate at age 20–24 has been reported in a prospective childhood asthma study, yet risk factors were not analysed in a multivariate way, preventing appropriate interpretation as to the relevance of the independent risk factors. To conclude, in children with moderate to severe asthma, childhood asthma status cannot predict whether or not symptoms of wheeze and asthma attacks will still be present in adulthood.

BHR was absent in 44 asthmatics (48%) at visit 3 and this was associated with a higher FEV₁% predicted at visit 1 and a lower total IgE at visit 2. Ulrik and Backer followed 7–17 year old asthmatic children. After 6 years more severe BHR was associated with a lower FEV₁% predicted and atopy at enrolment. Two other studies in children, one cross sectional and the other longitudinal in design, showed that the prevalence of BHR significantly increased with higher serum total IgE levels. Finally, a study in adults with asthma also showed that higher total IgE was associated with persistence of BHR. Thus, although the underlying mechanism has yet to be determined, higher IgE levels appear to constitute a risk factor for persistence of BHR. Twenty of our asthma patients (22%) were in complete remission of asthma and 47 patients (52%) were asymptomatic and without inhaled corticosteroids at follow up, a definition used to express clinical remission of asthma. Twenty seven of the latter group (57%) had BHR or a low lung function, or both. This is in line with the study of Boulet et al who found that asymptomatic asthmatic subjects who did not use medication still had active disease, as shown by lower lung function values, increased bronchodilator response, and BHR suggesting either ongoing airway
inflammation or airway remodelling. Indeed, a recent study\(^6\) showed that asthma patients with a comparable definition of remission\(^7\) had higher numbers of eosinophils, T cells, mast cells, and IL-5 in the airway mucosa compared to healthy control subjects. Another study\(^8\) found higher numbers of eosinophils in the bronchoalveolar lavage fluid of atopic children who had apparently outgrown their asthma (no wheezing for 12 months and no current medication) compared with controls. Thus, simply asking patients whether they have asthma symptoms and use asthma treatment is unreliable for determining airway inflammation as well as asthma remission. It remains to be established whether this has consequences for clinical practice—that is, institution of anti-inflammatory treatment.

We conclude that complete remission of asthma is only present in a small subset of this clinic based sample of atopic patients with moderate to severe asthma. Importantly, we show variable results in the outcome of asthma dependent on whether remission is defined as absence of symptoms, (near) normal lung function, absence of BHR, no use of asthma medication, or as a combination of these components. Only 22% of symptomatic allergic asthmatic children fully outgrew their asthma by age 32–42, determined on the basis of a combination of objective and subjective measurements. Remission of asthma is associated with better lung function early in life and a higher increase in lung function from age 5–14 to age 21–33. This possibly reflects a lower prevalence of early and/or progressive airway remodelling in those patients with a better outcome of the disease. Our results support the idea that defining remission of asthma by only assessing symptoms and medication use will overlook those subjects who have subclinical active disease and possibly associated airway remodelling.

Authors’ affiliations
J M Vonk, H M Boezen, J P Schouten, Department of Epidemiology, University of Groningen, The Netherlands
D S Postma, G H Koeter, Department of Pulmonology, University Hospital and University of Groningen, The Netherlands
M H Grol, J Gerritsen, Department of Pediatric Pulmonology, University Hospital and University of Groningen, The Netherlands

This study was supported by The Netherlands Asthma Foundation (grant number 93.64) and Stichting Astma Bestrijding.

REFERENCES
Childhood factors associated with asthma remission after 30 year follow up

J M Vonk, D S Postma, H M Boezen, M H Grol, J P Schouten, G H Koëter and J Gerritsen

Thorax 2004 59: 925-929
doi: 10.1136/thx.2003.016246

Updated information and services can be found at:
http://thorax.bmj.com/content/59/11/925

These include:

References
This article cites 29 articles, 5 of which you can access for free at:
http://thorax.bmj.com/content/59/11/925#BIBL

Email alerting service
Receive free email alerts when new articles cite this article. Sign up in the box at the top right corner of the online article.

Topic Collections
Articles on similar topics can be found in the following collections

Asthma (1782)
Child health (843)
Drugs: respiratory system (526)

Notes

To request permissions go to:
http://group.bmj.com/group/rights-licensing/permissions

To order reprints go to:
http://journals.bmj.com/cgi/reprintform

To subscribe to BMJ go to:
http://group.bmj.com/subscribe/